ArticleScientific reports2026
Development and validation of a clinical prediction model for the success of focused ultrasound ablation system for the treatment of adenomyosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and validate a clinical prediction model for the success of the focused ultrasound ablation system (FUAS) in treating adenomyosis. A retrospective analysis was conducted on 250 patients from Qingdao Women and Children's Hospital (2019-2022). Patients were categorized into success (n = 108) or failure (n = 142) groups based on a post-treatment lesion ablation rate greater than 80%. The dataset was split into training (70%) and validation (30%) sets. The multivariable analysis identified age (OR = 1.10, P = 0.014), depth of adenomyosis (OR = 1.03, P = 0.036), and uterine body (OR = 0.25, P = 0.027) as independent predictors of FUAS efficacy, which were used to build the model. In the training set, the model achieved an AUC of 0.74 for efficacy prediction. The Bootstrap ROC indicates an AUC mean of 0.751 with a standard deviation of 0.036. In conclusion, a model based on age, depth of ademyosis, and uterine body lesions treatment dose accurately predicts FUAS success for adenomyosis. This tool can aid clinical decision-making and promote personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.